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An Unﬁnished Story*Marco Metra, MD, Carlo Lombardi, MDU p to one-half of patients with heart failure(HF) have preserved ejection fraction(HFpEF). Although treatment of patients
with HF and reduced ejection fraction (HFrEF) is
well established and based on evidence from multiple
randomized clinical trials, no evidence has been ob-
tained to support any speciﬁc treatment for patients
with HFpEF (1). Angiotensin-converting enzyme in-
hibitors (ACEIs) and angiotensin receptor blockers
(ARBs) stand as major examples of such discrepancy.
Although clinical trials have clearly shown their efﬁ-
cacy in patients with HFrEF, we have seen neutral
results in patients with HFpEF (2–4). This outcome
is despite their antihypertrophic and antiﬁbrotic
effects, which should make both drug classes poten-
tially useful for treating HFpEF. The lack of favorable
results potentially stem from difﬁculties in the diag-
nosis of HFpEF, patient heterogeneity, differences
in the pathophysiology, and higher noncardiovas-
cular mortality (5,6). In this issue of the Journal,
Damman et al. (7) demonstrate major differences in
the signiﬁcance of worsening renal function (WRF)
in patients with HFpEF, compared with those with
HFrEF, thus adding additional data about differences
between these 2 clinical syndromes.SEE PAGE 1106Renal dysfunction and WRF are associated with a
poor prognosis in patients with HF (8,9). We know
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volume overload, electrolyte abnormalities, and
neurohormonal and inﬂammatory activation (8).
Accordingly, protection from WRF has been included
as an endpoint ofmajor clinical trials (10–13). However,
the clinical signiﬁcance of WRF may vary according to
its causes and a patient’s clinical condition. A transient
increase in serum creatinine values and, thus, WRF,
according to its traditional deﬁnition, may be caused
by excessive diuresis with volume contraction and
transient renal hypoperfusion (10–12,14,15). Similarly,
a drop in blood pressure (BP), due to excessive vaso-
dilation, may also increase serum creatinine levels
(16,17). As opposed to episodes of WRF occurring with
persistent congestion and ﬂuid overload, episodes of
serum creatinine escalation, caused by overdiuresis or
hypotension, are generally transient and not associ-
ated with a worse prognosis (14,15,17).
Initiation of an ACEI or ARB in patients with HFrEF
offers another example of the lack of prognostic sig-
niﬁcance of WRF. Activation of the renin-angiotensin
system allows maintenance of glomerular perfusion
pressure and glomerular ﬁltration rate (GFR), despite
reductions in cardiac output and BP, through prefer-
ential constriction of the efferent glomerular arteriole
in patients with HF. Blocking the effects of angio-
tensin II causes glomerular efferent arteriole dilation
with a drop in glomerular perfusion pressure, a lower
GFR, and an increase in serum creatinine (Figure 1)
(8,18). These changes, however, provide no unfavor-
able prognostic signiﬁcance, and a slight increase in
serum creatinine is an expected consequence when
initiating ACEI therapy (1,17,19).
The data regarding the renal effects of ACEI or ARB
initiation have all been obtained in patients with
HFrEF. With only one exception (20), the prognostic
value of WRF in HFpEF patients has not yet been
studied. Damman et al. (7) analyzed the association
Angiotensin II
ARB ARB
preglomerular
arteriole
resistance
postglomerular
arteriole resistance
GFR
P
BP
FIGURE 1 Effects of an ARB on Renal Function
The effects are shown in red and with dashed lines. Angiotensin II
secretion causes constriction of the afferent and, to a larger
extent, efferent glomerular arteriole, which maintain glomerular
ﬁltration rate (GFR) despite a low cardiac output and blood
pressure (BP) in patients with heart failure. Blockade of the renin-
angiotensin system, such as with angiotensin receptor blocker
(ARB) administration, causes dilation of the glomerular arterioles
with a decrease in glomerular perfusion pressure (DP) and GFR.
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1115between WRF and outcome in 3,595 patients enrolled
in the I-PRESERVE (Irbesartan in Heart Failure With
Preserved Ejection Fraction) trial. WRF was assessed
8 weeks’ post-randomization and deﬁned on the basis
of changes in serum creatinine from baseline.
Patients receiving irbesartan had a larger decrease in
estimated GFR (eGFR) and a greater likelihood to
develop WRF, compared with those receiving placebo
(8% vs. 4%). Importantly, and different from results
in patients with HFrEF, WRF was associated with a
higher risk of cardiovascular death or HF hospitali-
zation in the overall patient population and in the
irbesartan treatment group but not in the placebo
group. These results persisted after adjustment for
baseline variables by multivariable analysis (hazard
ratio of the patients with WRF: 1.43 [95% conﬁdence
interval: 1.10 to 1.85]; p ¼ 0.008 in all patients; hazard
ratio of the patients with WRF: 1.66 [95% conﬁdence
interval: 1.21 to 2.28]; p ¼ 0.002 in those receiving
irbesartan).
We would expect to ﬁnd WRF developing in the
patients receiving irbesartan in the I-PRESERVE study,
consistent with the data in patients with HFrEF. In this
case, its mechanism seems mainly related to hypo-
tension (7,17,19). Patients developing WRF withirbesartan had a larger BP drop at week 8, compared
with those without WRF. BP changes showed a sig-
niﬁcant association with changes in eGFR, and there
was a signiﬁcant multivariate adjusted interaction
among irbesartan treatment allocation, changes in BP,
and change in eGFR (7).
The independent association of WRF on irbesartan
with worse cardiovascular outcomes and all-cause
mortality is a rather unexpected, unprecedented,
and intriguing result of this study. WRF after initia-
tion of ACEI therapy is associated with a better
prognosis, and it actually has been considered a
marker of therapeutic efﬁcacy, in patients with HFrEF
(17,19). The results of the present study therefore
remain difﬁcult to explain. The ﬁrst and simplest
reason is that WRF has untoward effects that are not
counteracted by any improvement in cardiac and
vascular function in patients with HFpEF, unlike
those with HFrEF. Second, patients with HFpEF may
be more sensitive to the adverse effects of renal
dysfunction. Accordingly, markers of renal dysfunc-
tion, such as high cystatin C and increased urinary
albumin excretion, have been related to a higher
incidence of new-onset HFpEF in a community-based
cohort study (21) but not related to a worse prognosis
in other studies in patients with HF (22–25). Third,
WRF in HFpEF patients may be a marker of other
untoward effects of ARBs or ACEIs, such as excessive
vasodilation, which could cause an exaggerated drop
in BP in patients with HFpEF, partly due to the
steeper slope of their left ventricular pressure–
volume relationship (6).
Damman et al. (7) are to be commended for their
study, which adds another piece to the puzzle of the
complex relationships among the renin-angiotensin
system, renal function, and cardiac function. These
data in patients with HFpEF are likely to be replicated
by other studies and analyses. Although we are still
lacking data showing efﬁcacy of any treatment, at
least we are now aware of a new potential danger
associated with a treatment widely shown as life-
saving in other conditions, such as HFrEF and most
other cardiovascular conditions.
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